KPL-301 for Subjects With Giant Cell Arteritis

NCT03827018 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Giant Cell Arteritis

Interventions

COMBINATION_PRODUCT: mavrilimumab
COMBINATION_PRODUCT: placebo
DRUG: prednisone

Sponsor

Kiniksa Pharmaceuticals, Ltd.